Nanotechnology Now - Press Release: Reportlinker Adds Nanobiotechnology: Applications and Global Markets

Home > Press > Reportlinker Adds Nanobiotechnology: Applications and Global Markets

Abstract:
Reportlinker.com announces that a new market research report is available in its catalogue:

Nanobiotechnology: Applications and Global Markets

www.reportlinker.com/p0341184/Nanobiotechnology-Applications-and-Global-Markets.html

Reportlinker Adds Nanobiotechnology: Applications and Global Markets

New York, NY | Posted on December 20th, 2010

The total market for nanobiotechnology products is $19.3 billion in 2010 and is growing at a compound annual growth rate (CAGR) of 9% to reach a forecast market size of $29.7 billion by 2015.

Medical applications, including drug delivery and microbicides, dominate today's market, with sales of $19.1 billion in 2010. This market segment is growing at a compound annual growth rate (CAGR) of 8.7%, and is forecast to reach sales of $29 billion by 2015.

In the R&D tools market, DNA sequencing is an emerging growth opportunity for nanotechnologies. This sector is valued at $63 million in 2010 and is expected to increase at a 37% compound annual growth rate (CAGR) to reach $305 million in 2015.

STUDY GOALS AND OBJECTIVES

BCC's goal for this study is to examine the status of current and emerging nanobiotechnologies and products and assess their worldwide growth potential over a 5-year period from 2010 to 2015. We are particularly interested in characterizing the nanobiotechnology market for drug delivery, diagnostics, R&D tools, microbicides, and DNA sequencing applications. A main focus of this report is drug delivery, where the majority of nanotechnology sales occur.

Our main objective is to present a comprehensive analysis of what constitutes the state-of-the-art for nanotech-enabled life science products and what the current and future commercial potential is for each of the key market segments.

REASONS FOR DOING THE STUDY

Nanotechnology is coming of age as a materials platform in multiple industries including the biotechnology industry. The unique properties that nanomaterials provide enable value-added performance in a range of life science applications, from encapsulating and releasing drugs to biologic imaging. At the same time, the drug industry is searching for ways to extend drugs coming off patent as well as to improve drug pharmacokinetics. The diagnostics industry is seeking ways to better image molecular events to meet demand for new medicines. Nanobiotechnology, representing a diverse range of applications and materials, is the result of these converging forces.

Several nanotechnology platforms are already established and providing significant revenues in drug delivery applications, as well as diagnostics, microbicides, and R&D tools. Significant nanotechnology drug formats include polymer, liposomal, and nanocrystal drugs. Diagnostic and microbicide formats include nanoparticles, quantum dots, and dendrimers. Nanopore formats are emerging in third-generation DNA sequencing applications.

Given the emerging nature of this industry, it is timely to analyze the key trends, markets, and industry dynamics to provide a useful basis for decision-making.

INTENDED AUDIENCE

We have compiled a study of the main nanomaterials that will be important in the five major end-user segments. We present the nanobiotechnologies and growth-driving forces, product types, key market applications, companies and alliances, future market potential, and product sales forecasts for the period 2009 through 2015. We project the future use of nano-enabled products for the key end-use segments: R&D tools, drug delivery, diagnostics, microbicides, and DNA sequencing.

We also examine the changing industry dynamics, key nanomaterials and their applications, and markets.

This study will be of particular interest to the companies in the following industries: diagnostics, pharmaceuticals, biotechnology, nanomaterials, life sciences tools, biodefense, medical devices, polymers, DNA sequencing, and medical and biologic imaging materials.

It will also be of interest to manufacturers of quantum dots, dendrimers, nanoparticles, nanocrystals, nanopores, biochips, and polymer nanoparticles.

SCOPE OF REPORT

The study scope includes the major nanotechnology formats that are likely to become commercialized within the next 5 years. Each technology format is analyzed to determine its market status, impact on future market segments, and forecasted growth from 2010 through 2015. Technology issues and market-driving forces are discussed.

Influencing factors, including drug delivery needs, biologic imaging trends, industry structure, and patent trends, are also discussed.

BCC examines nanobiotechnology companies and industry alliances, nanomaterial consumption by end-user industry, and market-driving forces. We profile 115 nanobiotechnology companies.

METHODOLOGY

BCC presents an analysis of each of the key market segments that will be commercially important during the next 5 years: research tools, drug delivery, diagnostics, next-generation DNA sequencing, and microbicides.

Based on our analysis, we evaluate the potential applications of nanomaterial platforms in each of the major market segments and forecast sales revenues for 2010 through 2015.

For research tools and drug discovery and development, the study presents a forecast from 2010 through 2015 for each of the important nanomaterials and applications. For drug delivery, we forecast the market by nanomaterial and by clinical indication. For diagnostics, the report forecasts from 2010 through 2015 the demand by application, modality, and nanomaterial. For microbicides, the report forecasts from 2010 through 2015 the demand by application and nanomaterial. For DNA sequencing, the study forecasts market size by use and by sequencing generation. Finally, we forecast the overall nanobiotechnology market by geographical region.

INFORMATION SOURCES

BCC surveyed life science companies and research institutions to obtain data for this study. Included were research tool firms, diagnostics firms, drug firms, nanomaterials firms, and leading nanotechnology research institutions. In addition, we compiled data from secondary sources including industry, trade, and government

ANALYST CREDENTIALS

John Bergin has written previous BCC Research biotechnology reports, titled Epigenomics: DNA Sequencing: Emerging Technologies and Applications; Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics; Global Biochip Markets: Microarrays and Lab-on-a-Chip; RNA Interference in the Post-Genomics Era: Markets and Technologies; Synthetic Biology: Emerging Global Markets; Biologic Imaging Reagents: Technologies and Global Markets. Mr. Bergin has held business development, sales, and marketing positions with a Fortune 500 advanced materials company as well as executive management positions with a nanotechnology company. Mr. Bergin holds the following degrees: B.S. Chemistry, M.S. Biotechnology, and Masters of Business Administration.

Chapter- 1: INTRODUCTION -- Complimentary

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

INTENDED AUDIENCE 2

SCOPE OF REPORT 2

METHODOLOGY 2

INFORMATION SOURCES 3

ANALYST CREDENTIALS 3

RELATED BCC REPORTS 3

BCC ONLINE SERVICES 4

DISCLAIMER 4

Chapter-2: SUMMARY

SUMMARY 5

SUMMARY TABLE GLOBAL VALUE OF NANOBIOTECHNOLOGY MARKET, BY END USER, THROUGH 2015 ($ MILLIONS) 6

SUMMARY FIGURE GLOBAL VALUE OF NANOBIOTECHNOLOGY MARKET, BY END USER, 2009- 2015 ($ MILLIONS) 6

SUMMARY (CONTINUED) 7

Chapter-3: OVERVIEW

INTRODUCTION 8

TABLE 1 SCOPE OF THIS REPORT 8

MARKET POTENTIAL OF NANOBIOTECHNOLOGY 9

TABLE 2 GLOBAL VALUE OF NANOBIOTECHNOLOGY MARKET, BY APPLICATION, THROUGH 2015 ($ MILLIONS) 9

NANOBIOTECHNOLOGY GROWTH DRIVING FORCES 10

TABLE 3 NANOBIOTECHNOLOGY MARKET GROWTH DRIVING FORCES 10

NANOBIOTECHNOLOGY MATERIALS PLATFORMS 11

TABLE 4 GLOBAL VALUE OF NANOBIOTECHNOLOGY MARKET, BY PLATFORM, THROUGH 2015 ($ MILLIONS) 11

NANOBIOTECHNOLOGY PRODUCT LIFE CYCLE STATUS 12

TABLE 5 LIFE CYCLE STATUS OF NANOMATERIALS 12

NANOBIOTECHNOLOGY INDUSTRY 12

TABLE 6 NANOBIOTECHNOLOGY INDUSTRY 13

NANOBIOTECHNOLOGY INDUSTRY (CONTINUED) 14

Chapter-4: NANOBIOTECHNOLOGIES

NANOBIOTECHNOLOGY 15

TABLE 7 FEATURES OF NANOTECHNOLOGIES 15

HISTORY OF NANOTECHNOLOGY 15

TABLE 8 HISTORICAL TIMELINE OF NANOTECHNOLOGY, 1931- 2007 16

NANOTECHNOLOGY VALUE CHAIN 17

TABLE 9 VALUE CHAIN FOR NANOTECHNOLOGIES 18

BIO-NANOMATERIALS 18

OVERVIEW 18

TABLE 10 NANOBIOTECHNOLOGY MATERIALS 18

APPLICATIONS STATUS 19

TABLE 11 NANOMATERIALS APPLICATIONS STATUS 19

LIFE CYCLE STATUS 20

TABLE 12 NANOMATERIALS LIFE CYCLE STATUS 21

NANOPARTICLES 21

NANOPARTICLES (CONTINUED) 22

TABLE 13 NANOPARTICLES IN IMAGING APPLICATIONS 23

QUANTUM DOTS 24

TABLE 14 COMPARISON OF QUANTUM DOTS, FLUORESCENT DYES AND FLUORESCENT PROTEINS 25

FIGURE 1 QUANTUM DOT SPECTRA 25

FIGURE 2 FLUORESCENT DYE SPECTRA 26

LIPOSOMES 27

TABLE 15 LIPOSOME TYPES 28

DENDRIMERS 28

NANOPORES 29

TECHNICAL FEASIBILITY OF NANOPORE SEQUENCING 30

NANOCRYSTALS 31

TABLE 16 ADVANTAGES OF NANOCRYSTAL DRUG TECHNOLOGY 32

POLYMER STRUCTURES 33

INTEGRATED NANOSTRUCTURES 33

INTEGRATED NANOSTRUCTURES (CONTINUED) 34

INTEGRATED NANOSTRUCTURES (CONTINUED) 35

Chapter-5: NANOBIOTECHNOLOGY APPLICATIONS

INTRODUCTION 36

TABLE 17 NANOBIOTECHNOLOGY MATERIALS/APPLICATIONS MATRIX 36

DRUG DELIVERY APPLICATIONS 37

TABLE 18 BENEFITS OF IMPROVED DRUG DELIVERY 37

TABLE 19 KEY NANOMATERIALS IN DRUG DELIVERY 38

TABLE 20 NUMBER OF COMMERCIAL DRUGS USING NANOTECHNOLOGY, BY INDICATION, SEPTEMBER 2010 38

TABLE 21 MARKETED NANO-BASED DRUGS, 2010 39

TABLE 21 (CONTINUED) 40

TABLE 22 STATUS OF AMPHOTERICIN B 41

TARGETED DELIVERY 42

TABLE 23 TARGETED VERSUS NONTARGETED DRUG DELIVERY 43

SIRNA DRUG DELIVERY 43

FIGURE 3 RNAI SYSTEMIC DELIVERY APPROACHES 44

BIOLOGIC IMAGING APPLICATIONS 45

TABLE 24 KEY BIOLOGIC IMAGING NANO-REAGENT TYPES 46

WHY NANOPARTICLES ARE IMPORTANT FOR IMAGING 47

SUMMARY OF NANOPARTICLE IMAGING APPLICATIONS 48

TABLE 25 NANOPARTICLES IN IMAGING APPLICATIONS 49

In Vivo Imaging 49

TABLE 26 NANOPARTICLE IN VIVO DIAGNOSTICS PIPELINE 50

TABLE 26 (CONTINUED) 51

In Vitro Imaging 52

TABLE 27 NANOSPHERE IN VITRO DIAGNOSTICS REAGENTS PIPELINE 52

Genomics, Proteomics and Cell Biology Imaging 53

EMERGING APPLICATIONS OF IMAGING REAGENTS 53

FIGURE 4 THREE COMPONENTS OF ADVANCED IMAGING REAGENT TECHNOLOGY 54

ADVANCED IMAGING NANO-REAGENTS 55

TABLE 28 EMERGING BIOLOGIC NANO-IMAGING REAGENT FUNCTIONS 55

Dual Modality Reagents 55

Multifunctional Reagents 56

Multiplexed Reagents 57

SEQUENCING APPLICATIONS 57

TABLE 29 SEQUENCING KEY NANOMATERIALS 58

TABLE 30 USE OF NANOMATERIALS, BY SEQUENCING PLATFORM 58

SEQUENCING APPLICATIONS (CONTINUED) 59

FIGURE 5 $1,000 GENOME PROGRAM AWARDS, BY TECHNOLOGY, 2007-2009 60

RESEARCH TOOLS APPLICATIONS 61

MICROBICIDE APPLICATIONS 61

TABLE 31 APPLICATIONS OF NANOMATERIALS IN MICROBICIDES 62

Chapter-6: NANOBIOTECHNOLOGY INDUSTRY STRUCTURE

INDUSTRY OVERVIEW 63

TABLE 32 NANOBIOTECHNOLOGY MATERIALS/APPLICATIONS MATRIX 63

DRUG DELIVERY INDUSTRY 64

TABLE 33 DRUG DELIVERY INDUSTRY POSITION, BY NANOMATERIAL 65

TABLE 34 DRUG DELIVERY COMPETITOR POSITION 66

TABLE 34 (CONTINUED) 67

TABLE 34 (CONTINUED) 68

TABLE 34 (CONTINUED) 69

TABLE 35 COMPANIES SPECIALIZING IN DRUG DELIVERY OF BIOMOLECULES 69

NANOPORE SEQUENCING INDUSTRY 70

TABLE 36 SEQUENCING INSTRUMENT COMPETITORS, BY TECHNOLOGY 70

TABLE 36 (CONTINUED) 71

QUANTUM DOTS INDUSTRY 72

TABLE 37 QUANTUM DOTS KEY COMPETITORS 72

ACQUISITIONS AND STRATEGIC ALLIANCES 73

TABLE 38 NANOBIOTECHNOLOGY INDUSTRY ACQUISITIONS, 2007-2010 74

TABLE 39 NANOBIOTECHNOLOGY INDUSTRY STRATEGIC ALLIANCES, 2007-2010 75

TABLE 39 (CONTINUED) 76

ACQUISITIONS AND STRATEGIC � (CONTINUED) 77

ACQUISITIONS AND STRATEGIC � (CONTINUED) 78

Chapter-7: NANOBIOTECHNOLOGY MARKETS

MARKET GROWTH DRIVING FORCES 79

TABLE 40 NANOBIOTECHNOLOGY MARKET GROWTH DRIVING FORCES 79

TABLE 41 NANOBIOTECHNOLOGY PEER-REVIEWED PUBLICATIONS, 1990-2009 80

NANOBIOTECHNOLOGY MARKET SUMMARY 81

NANOPRODUCTS MARKETS BY PLATFORM 81

TABLE 42 GLOBAL VALUE OF NANOBIOTECHNOLOGY MARKET, BY PLATFORM, THROUGH 2015 ($ MILLIONS) 81

NANOPRODUCTS MARKETS BY APPLICATION 82

TABLE 43 GLOBAL VALUE OF NANOBIOTECHNOLOGY MARKET, BY APPLICATION, THROUGH 2015 ($ MILLIONS) 83

TABLE 44 GLOBAL VALUE OF RESEARCH TOOLS MARKET, BY APPLICATION, THROUGH 2015 ($ MILLIONS) 83

TABLE 45 GLOBAL VALUE OF RESEARCH TOOLS MARKET, BY NANOPLATFORM, THROUGH 2015 ($ MILLIONS) 84

DNA SEQUENCING MARKET 85

TABLE 46 GLOBAL VALUE OF NANOBIOTECHNOLOGY SEQUENCING MARKET, THROUGH 2015 ($ MILLIONS) 85

TABLE 47 GLOBAL VALUE OF SANGER AND NEXT-GENERATION NANO-ENABLED SAMPLE PREPARATION MARKET, BY SEQUENCING GENERATION, THROUGH 2015 ($ MILLIONS) 86

TABLE 48 GLOBAL VALUE OF THE NANO-ENABLED NANOPORE SEQUENCING MARKET, BY PRODUCT TYPE, THROUGH 2015 ($ MILLIONS) 86

TABLE 49 GLOBAL VALUE OF THE NANO-ENABLED SEQUENCING MARKET, BY NANOPLATFORM, THROUGH 2015 ($ MILLIONS) 87

DIAGNOSTICS MARKET 88

DIAGNOSTICS MARKET SUMMARY 88

TABLE 50 GLOBAL VALUE OF THE NANO-ENABLED DIAGNOSTICS MARKET, BY APPLICATION, THROUGH 2015 ($ MILLIONS) 88

TABLE 51 GLOBAL VALUE OF THE NANO-ENABLED DIAGNOSTICS MARKET, BY MODALITY, THROUGH 2015 ($ MILLIONS) 89

Diagnostics Market Summary (Continued) 90

TABLE 52 GLOBAL VALUE OF THE NANO-ENABLED DIAGNOSTICS MARKET, BY NANO-PLATFORM, THROUGH 2015 ($ MILLIONS) 91

MRI MARKET 91

TABLE 53 GLOBAL VALUE OF THE NANO-ENABLED MRI DIAGNOSTICS MARKET, BY NANO-PLATFORM, THROUGH 2015 ($ MILLIONS) 92

IN VITRO DIAGNOSTICS MARKETS 93

TABLE 54 GLOBAL VALUE OF THE NANO-ENABLED IN VITRO DIAGNOSTICS MARKET, BY ASSAY TYPE, THROUGH 2015 ($ MILLIONS) 93

TABLE 55 GLOBAL VALUE OF THE NANO-ENABLED IN VITRO DIAGNOSTICS MARKET, BY NANO-PLATFORM, THROUGH 2015 ($ MILLIONS) 94

IN VITRO DIAGNOSTICS NANOPARTICLES MARKETS 95

TABLE 56 GLOBAL VALUE OF NANOPARTICLE IN VITRO DIAGNOSTICS, BY NANO-PLATFORM, THROUGH 2015 ($ MILLIONS) 95

TABLE 57 GLOBAL VALUE OF GOLD NANOPARTICLE IN VITRO DIAGNOSTICS, BY APPLICATION, THROUGH 2015 ($ MILLIONS) 96

MICROBICIDES MARKET 96

TABLE 58 GLOBAL VALUE OF THE NANO-ENABLED MICROBICIDES MARKET, BY APPLICATION, THROUGH 2015 ($ MILLIONS) 96

FIGURE 6 BRANDED CONDOM MANUFACTURER WORLDWIDE MARKET SHARES, 2010 (%) 97

FIGURE 6 (CONTINUED) 98

TABLE 59 GLOBAL VALUE OF NANO-ENABLED MICROBICIDES MARKET, BY PLATFORM, THROUGH 2015 ($ MILLIONS) 98

DRUG DELIVERY MARKET 99

TABLE 60 GLOBAL VALUE OF DRUG DELIVERY NANOPRODUCTS MARKET, BY INDICATION, THROUGH 2015 ($ MILLIONS) 100

TABLE 61 GLOBAL VALUE OF THE NANO-ENABLED DRUG DELIVERY MARKET, BY TECHNOLOGY PLATFORM, THROUGH 2015 ($ MILLIONS) 101

TABLE 62 GLOBAL VALUE OF THE NANO-ENABLED CANCER DRUG DELIVERY MARKET, BY TECHNOLOGY PLATFORM, THROUGH 2015 ($ MILLIONS) 102

TABLE 63 GLOBAL VALUE OF NANO-ENABLED CNS DRUG DELIVERY MARKET, BY TECHNOLOGY PLATFORM, THROUGH 2015 ($ MILLIONS) 103

TABLE 64 GLOBAL VALUE OF NANO-ENABLED ANTI-INFECTIVE DRUG DELIVERY MARKET, BY TECHNOLOGY PLATFORM, THROUGH 2015 ($ MILLIONS) 104

TABLE 65 GLOBAL VALUE OF NANO-ENABLED LIPID DISORDER DRUG DELIVERY MARKET, BY TECHNOLOGY PLATFORM, THROUGH 2015 ($ MILLIONS) 105

TABLE 66 GLOBAL VALUE OF NANO-ENABLED "OTHER" DRUG DELIVERY MARKET, BY TECHNOLOGY PLATFORM, THROUGH 2015 ($ MILLIONS) 106

NANOBIOTECHNOLOGY MARKETS BY GEOGRAPHY 106

TABLE 67 GLOBAL VALUE OF NANOBIOTECHNOLOGY MARKET, BY GEOGRAPHY, THROUGH 2015 ($ MILLIONS) 107

Chapter-8: NANOBIOTECHNOLOGY PATENT STATUS

NANOBIOTECHNOLOGY PATENTS BY GEOGRAPHY 108

FIGURE 7 NUMBER OF NANOBIOTECHNOLOGY PATENTS BY GEOGRAPHY, 2000 TO SEPTEMBER 2010 108

FIGURE 7 (CONTINUED) 109

DRUG DELIVERY PATENTS 109

FIGURE 8 NUMBER OF DRUG DELIVERY NANOBIOTECHNOLOGY PATENTS BY NANOMATERIAL PLATFORM, 2000 TO SEPTEMBER 2010 110

FIGURE 9 NUMBER OF DRUG DELIVERY NANOBIOTECHNOLOGY PATENTS BY GEOGRAPHY, 2000 TO SEPTEMBER 2010 (%) 111

FIGURE 10 NUMBER OF LIPOSOMAL DRUG DELIVERY PATENTS BY GEOGRAPHY, 2000 TO 2010 112

FIGURE 10 (CONTINUED) 113

FIGURE 11 NUMBER OF NANOPARTICLE DRUG DELIVERY PATENTS BY GEOGRAPHY, 2000 TO SEPTEMBER 2010 113

FIGURE 11 (CONTINUED) 114

Chapter-9: COMPANY PROFILES

ABBOTT GMBH & CO. KG 115

ABRAXIS BIOSCIENCE 115

ACCESS PHARMACEUTICALS, INC. 116

ACUSPHERE, INC. 117

TABLE 68 ACUSPHERE PRODUCT PIPELINE 117

TABLE 69 ACUSPHERE PATENT ESTATE 118

ACRYMED, INC. 118

AION DIAGNOSTICS 119

ALNIS BIOSCIENCES INC. 120

AMAG PHARMACEUTICALS, INC. 120

TABLE 70 AMAG MOLECULAR IMAGING REAGENTS PIPELINE 121

TABLE 71 AMAG MRI IMAGING REAGENTS MARKETING ALLIANCES 122

AGILENT TECHNOLOGIES, INC. 122

AGILENT TECHNOLOGIES, INC.(CONTINUED) 123

ALLERGAN, INC. 124

ALLTRACEL PHARMACEUTICALS, PLC 124

ALPHA RX, INC. 125

ANSON NANO-BIOTECHNOLOGY CO. LTD. 125

APHIOS CORPORATION 125

AQUANOVA AG 126

ARMAGEN TECHNOLOGIES, INC. 126

ARTIFICIAL CELL TECHNOLOGIES, INC. 126

AZAYA THERAPEUTICS 127

BASE4 INNOVATION LTD. 127

BAXTER INTERNATIONAL INC. 128

BBI INTERNATIONAL 128

BILCARE LIMITED 129

BIND BIOSCIENCES, INC. 129

BIOALLIANCE PHARMA 130

BIOCON 131

BIODELIVERY SCIENCES INTERNATIONAL, INC. 131

BIO-GATE AG 132

BIONANOMATRIX, INC. 132

BIOPHAN TECHNOLOGIES, INC. 133

BIOSANTE PHARMACEUTICALS INC. 133

BIO-SYNECTICS, INC. 134

CALANDO PHARMACEUTICAL 134

CAMURUS AB 135

CAPSULUTION PHARMA AG 136

CELSION CORPORATION 136

TABLE 72 CELSION LIPOSOMAL PLATFORM STATUS 137

CENTOCOR ORTHO BIOTECH INC. 137

CERAMISPHERE PTY LTD 138

CERULEAN PHARMA INC. 138

CHEMICELL GMBH 139

CRITITECH, INC. 139

CSL BEHRING 140

CYTIMMUNE SCIENCES, INC. 140

DAMAGE PREVENTION CONCEPT 140

DENDRITECH, INC. 141

ELAN CORPORATION PLC 141

ELECTRONIC BIO SCIENCES 142

ENDOCYTE 143

ENZON PHARMACEUTICALS 143

EPITARGET AS 144

EVIDENT TECHNOLOGIES 144

EXILICA LIMITED 145

FERROPHARM GMBH 145

FLAMEL TECHNOLOGIES 146

FRESNIUS KABI AG 146

GE HEALTHCARE UK LTD. 147

GILEAD SCIENCES, INC. 147

GRACEWAY PHARMACEUTICALS, LLC 148

HANA BIOSCIENCES, INC. 148

HUMAN GENOME SCIENCES 148

IMMUNOVACCINE 149

INDIANA NANOTECH LLC 149

INTERNATIONAL BUSINESS MACHINES CORP. 150

JOHNSON & JOHNSON, INC. 150

KEREOS, INC. 151

TABLE 73 KEREOS IMAGING REAGENTS PIPELINE 152

TABLE 74 KEREOS STRATEGIC ALLIANCES 153

LABOPHARM INC. 153

LIFECARE INNOVATIONS PVT. LTD. 154

LIPLASOME PHARMA APS 154

LIPOXEN 155

LUNA NANOWORKS 156

MARINA BIOTECH 157

MINGYUAN MEDICARE DEVELOPMENT COMPANY LTD. 157

MYMETICS S.A. 158

NABSYS, INC. 158

NANOBIO CHEMICALS INDIA PRIVATE LIMITED 159

NANOBIOTIX 159

NANOBIOSYM, INC. 160

NANOCARRIER CO., LTD. 160

NANOCO TECHNOLOGIES LTD. 161

NANOCOPOEIA, INC. 162

NANOCYTE INC. 162

NANOPROBES, INC. 163

NANOSPECTRA BIOSCIENCES, INC. 164

NANOSPHERE, INC. 164

NANOTOX 165

NANOVECTOR, INC. 165

NATCO PHARMA LIMITED 165

NOVAVAX, INC. 166

NOVOSOM AG 166

NOVOZYMES BIOPHARMA US INC. 166

OCTOPLUS N.V. 167

OXFORD NANOPORE TECHNOLOGIES LTD. 167

OXFORD NANOPORE TECHNOLOGIES LTD. (CONTINUED) 168

OXONICA INC. 169

PACIRA PHARMACEUTICALS 169

PANACEA BIOTEC LTD. 170

PCI BIOTECH AS 170

SALVONA TECHNOLOGIES INC. 171

SCHERING-PLOUGH 171

SELAH TECHNOLOGIES, LLC 172

SELECTA BIOSCIENCES 172

SEQUENOM, INC. 173

SEQUENOM, INC. (CONTINUED) 173

SEQUENOM, INC. (CONTINUED) 174

SEQUENOM, INC. (CONTINUED) 175

SIEMENS AG 176

SIGMA-TAU PHARMACEUTICALS, INC. 176

SKYEPHARMA PLC 177

SMITH & NEPHEW PLC 178

SNOGG AS 178

SOPHERION THERAPEUTICS, LLC 178

STARPHARMA HOLDINGS LTD 179

TABLE 75 STARPHARMA STRATEGIC ALLIANCES 180

SUPRATEK PHARMA 181

TEKMIRA PHARMACEUTICALS 181

TEVA PHARMACEUTICALS 181

UNIDYM, INC. 182

VIVE NANO INC. 182